• CR Boya Bio-pharmaceutical, China Resources Pharmaceutical Group's subsidiary, posted nine-month net profit of RMB 60.59 million versus year-earlier RMB 343.04 million.
• The unaudited results, released October 29, 2026, cover the nine months ended September 30, 2026.
• Revenue fell to RMB 846.91 million from RMB 1.47 billion a year earlier.
• Cash and cash equivalents declined by RMB 81.34 million, compared with a year-earlier decrease of RMB 536.82 million.
• Period-end cash and cash equivalents stood at RMB 442.27 million versus RMB 761.75 million a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261029-12387580), on October 29, 2026, and is solely responsible for the information contained therein.